Ocrelizumab in PPMS. Complementing Regulatory History with a Decade of Clinical Evidence

Why It Matters

With no alternative approved options, ocrelizumab’s proven efficacy and long‑term safety provide a critical treatment avenue for a historically underserved MS population, shaping clinical practice and market dynamics.

Key Takeaways

• Ocrelizumab remains the sole FDA‑approved therapy for primary progressive MS
• O’HAND (2025) showed 33% EDSS risk reduction vs placebo
• Women experienced a 47% risk reduction in disability progression
• Ten‑year data indicate 30% lower wheelchair‑dependency risk with early treatment
• Over 1.44 million patient‑years show no new safety signals, including breast cancer

Pulse Analysis

The regulatory path of ocrelizumab illustrates how early FDA concerns were systematically addressed. Initially approved in 2017 after the ORATORIO trial demonstrated a modest slowing of disability, Roche responded to FDA queries on manufacturing consistency and data imputation methods. By 2024 the agency cleared a subcutaneous formulation, confirming that the product met stringent global quality standards without further manufacturing commitments, reinforcing confidence among clinicians and payers.

Efficacy data have expanded dramatically since ORATORIO. The 2025 O’HAND double‑blind trial validated the drug’s impact on both overall disability progression (33% risk reduction in EDSS) and upper‑limb function (32% risk reduction in 9‑Hole Peg Test). Notably, women achieved a 47% reduction in progression, dispelling earlier gender‑specific doubts. Benefits were also evident in patients lacking gadolinium‑enhancing lesions, confirming that ocrelizumab works across the full spectrum of PPMS disease activity.

Long‑term safety remains a cornerstone of ocrelizumab’s market position. With 1.44 million patient‑years of exposure, registries such as MANUSCRIPT and VERISMO have not identified new safety concerns, and breast‑cancer incidence aligns with background rates. Ten‑year follow‑up shows a sustained 30% lower risk of wheelchair dependency for early‑treated patients, underscoring durable clinical value. This robust benefit‑risk profile sustains Roche’s leadership in the PPMS space and sets a high bar for any future entrants.